[go: up one dir, main page]

ATE288749T1 - Verwendung von kannabidiol als entzündunghemmende mittel - Google Patents

Verwendung von kannabidiol als entzündunghemmende mittel

Info

Publication number
ATE288749T1
ATE288749T1 AT99915942T AT99915942T ATE288749T1 AT E288749 T1 ATE288749 T1 AT E288749T1 AT 99915942 T AT99915942 T AT 99915942T AT 99915942 T AT99915942 T AT 99915942T AT E288749 T1 ATE288749 T1 AT E288749T1
Authority
AT
Austria
Prior art keywords
cannabidiol
inflammatory agents
cannabinoids
inflammatory diseases
treating inflammatory
Prior art date
Application number
AT99915942T
Other languages
English (en)
Inventor
Marc Feldmann
Anne-Marie Malfait
Ruth Gallily
Raphael Mechoulam
Original Assignee
Kennedy Rheumatology Inst
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Rheumatology Inst, Yissum Res Dev Co filed Critical Kennedy Rheumatology Inst
Application granted granted Critical
Publication of ATE288749T1 publication Critical patent/ATE288749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99915942T 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel ATE288749T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE288749T1 true ATE288749T1 (de) 2005-02-15

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915942T ATE288749T1 (de) 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel

Country Status (12)

Country Link
US (1) US6410588B1 (de)
EP (1) EP1071417B1 (de)
JP (1) JP2002511411A (de)
AT (1) ATE288749T1 (de)
AU (1) AU757945B2 (de)
CA (1) CA2328368C (de)
DE (1) DE69923671T2 (de)
DK (1) DK1071417T3 (de)
ES (1) ES2241277T3 (de)
GB (1) GB9807639D0 (de)
IL (1) IL138979A0 (de)
WO (1) WO1999052524A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
CN1561990A (zh) * 1999-03-22 2005-01-12 免疫力药品有限公司 治疗免疫疾病
MXPA03003704A (es) 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
EP1206934A1 (de) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade von Natriumkanälen mit Phenolderivaten
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
JP4515908B2 (ja) * 2002-08-14 2010-08-04 ジーダブリュー・ファーマ・リミテッド 粘膜投与のためのカンナビノイド液体製剤
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
US20080262079A1 (en) * 2004-08-09 2008-10-23 Bernard Mach Cannabinoid Compositions and Methods of Use Thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP2007376B1 (de) 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutische verwendungen von cannabidiol-verbindungen
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ATE493977T1 (de) * 2007-10-02 2011-01-15 Vivacell Biotechnology Espana S L Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
WO2014178048A1 (en) 2013-05-02 2014-11-06 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
US10960035B2 (en) 2015-04-01 2021-03-30 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Voleaui Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066747A1 (en) * 2015-10-16 2017-04-20 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
JP2019533731A (ja) 2016-11-02 2019-11-21 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ Ｃｂｄとコパキソンの併用療法
EP3592345A4 (de) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) Zusammensetzungen und verfahren zur behandlung von entzündungskrankheiten
WO2019014851A1 (zh) * 2017-07-18 2019-01-24 汉义生物科技（北京）有限公司 大麻二酚在治疗肺动脉高压中的应用
WO2019034985A1 (en) * 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
WO2020081513A1 (en) * 2018-10-16 2020-04-23 Systamedic Inc. Novel compositions for the treatment of inflammatory diseases
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
JP7364839B2 (ja) * 2019-01-24 2023-10-19 漢義生物科技（北京）有限公司 創傷治癒を促進する医薬品の製造におけるカンナフラビンａの使用
WO2020167751A1 (en) * 2019-02-11 2020-08-20 Chancey John Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, ormonosaccharide
EP3962296A4 (de) * 2019-04-30 2023-02-08 Greenway Herbal Products, LLC Cannabinoidzusammensetzungen und verfahren zur verwendung
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CA3169702A1 (en) * 2020-04-02 2021-10-07 Joel Bradley LATHAM Methods and compositions for treating or preventing an inflammatory condition
EP4149446A1 (de) * 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Verwendungen und formulierungen von cannabinoiden
AU2021270970A1 (en) * 2020-05-11 2022-12-15 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
JP2023553335A (ja) 2020-11-24 2023-12-21 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド カンナビノイド誘導体、及び、炎症、疼痛又は肥満の治療におけるそれらの使用
AU2022309612A1 (en) * 2021-07-15 2024-02-01 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
EP4230201A1 (de) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
EP4482483A1 (de) 2022-02-21 2025-01-01 Universidade Nova De Lisboa Verbindungen und zusammensetzungen für neurodegenerative erkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) * 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
ES2241277T3 (es) 2005-10-16
DK1071417T3 (da) 2005-06-13
AU3436199A (en) 1999-11-01
DE69923671D1 (de) 2005-03-17
DE69923671T2 (de) 2006-03-16
EP1071417A1 (de) 2001-01-31
WO1999052524A1 (en) 1999-10-21
AU757945B2 (en) 2003-03-13
US6410588B1 (en) 2002-06-25
EP1071417B1 (de) 2005-02-09
IL138979A0 (en) 2001-11-25
CA2328368A1 (en) 1999-10-21
GB9807639D0 (en) 1998-06-10
CA2328368C (en) 2009-03-31
JP2002511411A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
ATE288749T1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
DK0882021T3 (da) Nye phenanthridiner
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
ATE312831T1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO994330D0 (no) Metode for behandling av en tumor
ATE109459T1 (de) Cyclopropylderivate als lipoxygenase-inhibitoren.
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
BG101126A (en) The use of muramylpeptide compounds
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69905602D1 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
CO5271719A1 (es) Composicion cosmetica adelgazante que contienen una substancia inductora de la produccion de il-6
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
GEP20012408B (en) Means for Treatment of Psoriasis
ECSP992841A (es) Nuevos derivados del acido dihidroxihexanoico
EA199800698A1 (ru) Способ лечения и фармацевтическая композиция

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties